OTCMKTS:NMUS Nemus Bioscience (NMUS) Stock Price, News & Analysis $0.78 -0.04 (-4.41%) As of 05/18/2026 Add Compare Share Share Stock Analysis Stock AnalysisChartBuy This Stock About Nemus Bioscience Stock (OTCMKTS:NMUS) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Nemus Bioscience alerts:Sign Up Key Stats Today's Range$0.76▼$0.8350-Day Range$0.58▼$1.0652-Week Range$0.05▼$0.74Volume102,665 shsAverage Volume377,395 shsMarket Capitalization$104.14 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Nemus Bioscience, Inc. is an early‐stage biopharmaceutical company developing proprietary prodrug cannabinoid therapeutics for ophthalmic, dermatological and metabolic diseases. The company leverages synthetic derivatives of naturally occurring cannabinoids, designed to improve bioavailability, tissue targeting and therapeutic efficacy. Nemus operates under an OTCMKTS listing and is headquartered in Houston, Texas. The company’s pipeline includes multiple preclinical candidates, with lead programs focusing on ophthalmic and dermatological indications. Nemus’ ophthalmic portfolio targets conditions such as diabetic retinopathy and glaucoma through topical prodrug formulations intended to enhance drug penetration into ocular tissues. Its dermatological programs are aimed at inflammatory skin disorders, utilizing cannabinoid prodrugs to deliver anti‐inflammatory effects while minimizing systemic exposure. In addition to eye and skin applications, Nemus is advancing metabolic disease programs, exploring cannabinoid prodrugs for non‐alcoholic fatty liver disease and obesity. The company employs in‐house chemistry and formulation expertise to optimize drug stability and performance. Nemus has established research collaborations with academic institutions to support preclinical pharmacology and toxicology studies, reinforcing its commitment to rigorous scientific validation. Leadership at Nemus Bioscience includes Chief Executive Officer Daniel Gould, who brings experience in pharmaceutical development and corporate strategy. Under his guidance, the company has prioritized strengthening its intellectual property portfolio and advancing its lead candidates toward regulatory milestones. Nemus continues to expand its research capabilities in North America, positioning itself to address unmet medical needs with novel cannabinoid‐based therapies.AI Generated. May Contain Errors. Read More Receive NMUS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Nemus Bioscience and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. NMUS Stock News HeadlinesReviewing Virios Therapeutics (NASDAQ:VIRI) and Nemus Bioscience (OTCMKTS:NMUS)May 15, 2026 | americanbankingnews.comYield10 Bioscience, Inc. (YTEN)April 19, 2024 | finance.yahoo.comElon Musk’s $1 Quadrillion AI IPO$1 quadrillion would be enough to send a $2.8 million check to every man, woman, and child in America. That is the scale of what analysts are calling the biggest AI IPO in history.And right now, you can claim a stake before the company goes public, starting with just $500.Elon Musk is predicting this investment could climb 1,000x from here. Early access is available today.May 19 at 1:00 AM | Brownstone Research (Ad)Assembly Biosciences Inc ASMBMarch 15, 2024 | morningstar.comMSagimet Biosciences Inc - Ordinary Shares - Class ASeptember 5, 2023 | money.usnews.comSatellos Bioscience Announces Closing of Previously Announced Non-Brokered Offering of $2.385 Million of Unsecured Non-Convertible DebenturesApril 27, 2023 | finance.yahoo.comCrown Bioscience Announces Transaction Closing of Indivumed's Service Business and Supporting BiobankApril 6, 2023 | finanznachrichten.dePsycheceutical Bioscience Provisional Patent Application for Novel Ketamine Topical for the Treatment of PTSDFebruary 24, 2023 | finance.yahoo.comSee More Headlines NMUS Stock Analysis - Frequently Asked Questions How have NMUS shares performed this year? Nemus Bioscience's stock was trading at $0.6603 at the start of the year. Since then, NMUS stock has increased by 17.8% and is now trading at $0.7777. How were Nemus Bioscience's earnings last quarter? Nemus Bioscience Inc (OTCMKTS:NMUS) announced its quarterly earnings results on Tuesday, May, 15th. The biopharmaceutical company reported ($0.09) EPS for the quarter. How do I buy shares of Nemus Bioscience? Shares of NMUS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Nemus Bioscience own? Based on aggregate information from My MarketBeat watchlists, some other companies that Nemus Bioscience investors own include Canopy Growth (CGC), Emerald Health Therapeutics (EMHTF), MedMen Enterprises (MMNFF), Aurora Cannabis (ACBFF), Kushco (KSHB), 22nd Century Group (XXII) and Cronos Group (CRON). Company Calendar Last Earnings5/15/2018Today5/19/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Pharmaceutical Preparations Sub-IndustryCannabis Current SymbolOTCMKTS:NMUS CIKN/A Webwww.nemusbioscience.com Phone949-396-0330FaxN/AEmployees11Year FoundedN/AProfitability EPS (Trailing Twelve Months)($0.09) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$19.19 million Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on Assets-924.42% Debt Debt-to-Equity RatioN/A Current Ratio0.12 Quick Ratio0.12 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value($0.12) per share Price / Book-6.48Miscellaneous Outstanding Shares133,908,000Free FloatN/AMarket Cap$104.14 million OptionableNot Optionable Beta-0.04 A Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for May 2026. Learn which stocks have the most short interest and how to trade them. Click the link to see which companies made the list.Get This Free Report This page (OTCMKTS:NMUS) was last updated on 5/19/2026 by MarketBeat.com Staff. From Our PartnersSpaceX eyes a 1.75 trillion valuation - here's what to knowElon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...Brownstone Research | SponsoredIran's New Leader Just Said Something That Should Terrify Every AmericanIran's Supreme Leader has declared the Strait of Hormuz closed as leverage against the U.S. - and with 40% of ...American Alternative | Sponsored$30 stock to buy before Starlink goes public (WATCH NOW!)In the next 3 minutes… James Altucher – legendary investor and venture capitalist… And someone who’s kno...Paradigm Press | SponsoredTrump's gold order: the announcement they won't put on the front pageOn August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredMy feud with Zohran MamdaniEmmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...Stansberry Research | SponsoredIran War Shock: What I Was Told In That Private MeetingYou’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...Banyan Hill Publishing | SponsoredWhy this tiny stock may move before the SpaceX IPO dropsThe projected SpaceX and xAI S-1 filing hits the SEC on June 1st - and analyst Dylan Jovine says $1.75 trillio...Behind the Markets | SponsoredSpaceX IPO hides a much bigger storyThe SpaceX IPO could be the biggest in history at $1.75 trillion - but the real story isn't the IPO itself. ...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Nemus Bioscience Inc Please log in to your account or sign up in order to add this asset to your watchlist. Share Nemus Bioscience With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
